Catalog No.
DHJ92702
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Ig epsilon chain C region, IGHE, Ig epsilon chain C region ND, Immunoglobulin heavy constant epsilon
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01854
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CL-2C, CAS: 1322627-61-1
Clone ID
Ligelizumab
Ligelizumab for Chronic Spontaneous Urticaria, PMID: 31577874
The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab, PMID: 31913280
Ligelizumab for the treatment of chronic spontaneous urticaria, PMID: 32380864
Ligelizumab for Chronic Spontaneous Urticaria, PMID: 32023385
Ligelizumab for chronic spontaneous urticaria, PMID: 32002982
Ligelizumab for Chronic Spontaneous Urticaria, PMID: 32023384
Ligelizumab for Chronic Spontaneous Urticaria. Reply, PMID: 32023387
Ligelizumab for Chronic Spontaneous Urticaria. Reply, PMID: 32023386
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects, PMID: 25200415
Ligelizumab Is Superior to Omalizumab for Chronic Spontaneous Urticaria, PMID: 32208012
New treatments for chronic urticaria, PMID: 31446134
Antibodies to watch in 2021, PMID: 33459118
Current and emerging treatments for chronic spontaneous urticaria, PMID: 31494233
Structure of intact IgE and the mechanism of ligelizumab revealed by electron microscopy, PMID: 32037590
High-Dose Omalizumab versus Ligelizumab for the Treatment of Chronic Spontaneous Urticaria: Do Not We Need a Head-To-Head Comparison?, PMID: 33321510
Ligelizumab treatment for severe asthma: learnings from the clinical development programme, PMID: 33747510
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses, PMID: 27185571
Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease, PMID: 32603278
Tailored therapy for severe asthma, PMID: 25671117
New biologics in the treatment of urticaria, PMID: 30015639
A Better IgE Trap to Control Urticaria, PMID: 31577881
Looking forward to new targeted treatments for chronic spontaneous urticaria, PMID: 28078079
An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases, PMID: 29290750
Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies, PMID: 31836406
Emerging Biomarkers and Therapeutic Pipelines for Chronic Spontaneous Urticaria, PMID: 30033912
Anti-IgE for the Treatment of Chronic Urticaria, PMID: 33628747
Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory Chronic Spontaneous Urticaria: A Systematic Review and Network Meta-analysis, PMID: 34431983
Advances in asthma in 2016: Designing individualized approaches to management, PMID: 28709967
The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid, PMID: 31636640
The use of biologics in food allergy, PMID: 33966304
Biologics for the Use in Chronic Spontaneous Urticaria: When and Which, PMID: 33685605
A Comprehensive Approach to Urticaria: From Clinical Presentation to Modern Biological Treatments Through Pathogenesis, PMID: 33385176
Quantitative in vitro and in vivo models to assess human IgE B cell receptor crosslinking by IgE and EMPD IgE targeting antibodies, PMID: 28647457
Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines, PMID: 33727832
For research use only. Not for human or drug use.
